Randomized Trialhigh evidence
Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
JAMA·July 30, 2026·PMID 42530910
Why it mattersAKI after cardiac surgery is common and lacks proven pharmacologic prevention. This trial provides robust evidence that a short course of dapagliflozin significantly lowers AKI risk, offering a potential new strategy for perioperative renal protection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled